Novo Nordisk stock falls as raised outlook fails to change the debate over obesity business
Novo Nordisk shares fell despite the company raising its full-year guidance, as investors remain concerned about pricing pressure and competition in the obesity drug market. Analysts are questioning the long-term growth potential of the company's current pipeline.
Why it matters
As a leader in the weight-loss drug market, Novo Nordisk's financial performance is a key indicator for the broader pharmaceutical industry.
Novo Nordisk 's CEO sought to reassure investors that its Wegovy pill can drive profitable growth despite lower prices, as investors sent the drugmaker's shares lower following quarterly results.
The Danish company raised its full-year guidance after reporting better-than-expected adjusted sales and operating profit, but investors remained focused on pricing pressure, the quality of the earnings beat and whether oral Wegovy can become a large enough growth driver to revive Novo's fortunes.
Novo said lower prices continued to weigh on sales, but CEO Mike Doustdar said that rising volumes and the early performance of the Wegovy pill showed the strategy was working.
"We would not be able to... show a positive growth on the top and the bottom if items like the pill were not doing well and were not profitable," Doustdar told CNBC's Carolin Roth on Wednesday.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in